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Abstract
Background: Astrocytes provide a vital support to neurons in normal and pathological conditions. In Alzheimer’s
disease (AD) brains, reactive astrocytes have been found surrounding amyloid plaques, forming an astrocytic scar.
However, their role and potential mechanisms whereby they affect neuroinflammation, amyloid pathology, and
synaptic density in AD remain unclear.
Methods: To explore the role of astrocytes on Aβ pathology and neuroinflammatory markers, we
pharmacologically ablated them in organotypic brain culture slices (OBCSs) from 5XFAD mouse model of AD and
wild-type (WT) littermates with the selective astrocytic toxin L-alpha-aminoadipate (L-AAA). To examine the effects
on synaptic circuitry, we measured dendritic spine number and size in OBCSs from Thy-1-GFP transgenic mice
incubated with synthetic Aβ42 or double transgenics Thy-1-GFP/5XFAD mice treated with LAAA or vehicle for 24 h.
Results: Treatment of OBCSs with L-AAA resulted in an increased expression of pro-inflammatory cytokine IL-6 in
conditioned media of WTs and 5XFAD slices, associated with changes in microglia morphology but not in density.
The profile of inflammatory markers following astrocytic loss was different in WT and transgenic cultures, showing
reductions in inflammatory mediators produced in astrocytes only in WT sections. In addition, pharmacological
ablation of astrocytes led to an increase in Aβ levels in homogenates of OBCS from 5XFAD mice compared with
vehicle controls, with reduced enzymatic degradation of Aβ due to lower neprilysin and insulin-degrading enzyme
(IDE) expression. Furthermore, OBSCs from wild-type mice treated with L-AAA and synthetic amyloid presented 56%
higher levels of Aβ in culture media compared to sections treated with Aβ alone, concomitant with reduced
expression of IDE in culture medium, suggesting that astrocytes contribute to Aβ clearance and degradation.
Quantification of hippocampal dendritic spines revealed a reduction in their density following L-AAA treatment in
all groups analyzed. In addition, pharmacological ablation of astrocytes resulted in a decrease in spine size in
5XFAD OBCSs but not in OBCSs from WT treated with synthetic Aβ compared to vehicle control.
Conclusions: Astrocytes play a protective role in AD by aiding Aβ clearance and supporting synaptic plasticity.
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Background
Astrocytes comprise 20% of the cells in the brain [1] and
play multiple roles in brain homeostasis. Their functions
include responding to CNS insults [2], providing meta-
bolic support (production of cholesterol and lactate),
regulating of the brain’s inflammatory response [1], and
performing supportive functions such as maintaining the
extracellular pH and ion content and aiding in the recyc-
ling of neurotransmitters such as glutamate and removal
of waste products [3]. When an insult occurs, astrocytes
become reactive and undergo astrogliosis [2]. This
causes a change in their morphology, becoming hyper-
trophic, as their cell body enlarges, and their processes
grow and develop into thick branches [4]. The presence
of astrogliosis is a classic feature of AD [1], and reactive
astrocytes are known to cluster around Aβ plaques,
forming a glial scar [5–7]. However, it is unclear the ex-
tent to which astrocytes may change their supportive
functions when they become reactive [3].
Whether reactive astrocytes have a beneficial or detri-
mental role in AD is debated [8]. They can cause dam-
age as they play a part in the perpetuation of chronic
inflammation [9]. They produce pro-inflammatory medi-
ators, such as nitric oxide [8], thus increasing neuroin-
flammation and the associated damage [1]. In addition,
they increase the levels of reactive oxygen species (ROS)
and produce hydrogen peroxide causing oxidative stress
[1]. While in the short term, this is advantageous as they
provide protection against insults, and the chronic acti-
vation of astrocytes may become damaging. In addition,
astrocytes may be involved in the generation of Aβ as
there is evidence that under inflammatory conditions,
they can express the components required for Aβ gener-
ation, i.e., APP, BACE1, and γ-secretase [10, 11].
On the other hand, reactive astrocytes can be neuro-
protective in the AD brain. They form a fibrous scar,
which helps to contain inflammation, and provide
trophic support to neurons by expressing neurotrophic
factors and regulate synaptic formation [5, 12]. In
addition, we and others have reported that reactive as-
trocytes are involved in the degradation and clearance of
Aβ [13, 14]. Astrocytes can produce Aβ peptidases, such
as neprilysin and IDE as well as the Apolipoprotein E
(ApoE) [15], which binds to and is involved in the clear-
ance of Aβ [16]. The use of genetic depletion of reactive
astrocytes has allowed the investigation into their role
in vivo. We have recently shown that the loss of prolifer-
ating astrocytes leads to increased amyloid levels and ex-
acerbated memory loss in the APP23 model of AD [17].
Besides using genetic models, there are other potential
strategies to determine the effect of astrocytic loss in
AD. One of them is the pharmacological ablation of as-
trocytes by incubating them with the glutamate analogue
L-alpha-aminoadipic acid (L-AAA), which causes
selective astrocytic toxicity and death [18]. This drug
binds to the cysteine glutamate antiporter, which is
expressed in astrocytes, but not in microglia or neurons,
allowing it to selectively target astrocytes. Because this
drug does not cross the BBB, we sought to investigate
the effect of pharmacological ablation of astrocytes in
organotypic cultures. The process of organotypic culture
involves culturing complete slices of brain tissue on
semipermeable membranes. This technique allows the
study of the brain in its original structure [19, 20]. Our
aim was to determine the role of pharmacological abla-
tion of astrocytes using organotypic cultures of the
5XFAD model of AD on neuroinflammatory markers,
amyloid pathology, and dendritic spine density.
Methods
Materials
The antibodies used for detection of proteins of interest
were 6E10 (against Aβ1-16) from Covance, R1(57)
against the carboxy terminus of APP was a kind gift
from Dr P. Mehta (NYS Institute for Basic Research in
Developmental Disabilities); anti-BACE1 was from Cell
Signaling; anti-apolipoprotein E (ApoE) and anti-
neprilysin CD10 from Santa Cruz; anti-ionized calcium-
binding adapter molecule 1 (IBA1) from Wako; anti-glial
fibrillary acidic protein (GFAP) (clone 2.2B10), anti-Aβ
(6C3), and anti-neuronal nuclei (NeuN) were from Milli-
pore; and anti-insulin degrading enzyme (IDE), Aldehyde
dehydrogenase 1A (Aldh1a1), and anti-β-actin were
from Abcam. Tissue culture reagents were purchased
from Invitrogen and Millipore, and all other reagents
were purchased from Sigma, unless stated otherwise.
Animal models
5XFAD transgenic (Jackson Laboratory) 7-day-old pups
were used for organotypic cultures, overexpressing in
their brains human APP (695) with the Swedish (K670N,
M671L), Florida (I716V), and London (V717I) muta-
tions, as well as human PS1 with the mutations M146L
and L286V [21]. 5XFAD mice were used because their
phenotype is more aggressive than other transgenic
models of amyloidosis and allow the detection of patho-
logical changes in brain slices after only 2 weeks in cul-
ture. Thy-1-GFP transgenic 7-day-old pups were used
for organotypic cultures, expressing membrane-bound
GFP [22].
Mice were kept in individually ventilated cages and
maintained on a 12/12-h light/dark cycle with controlled
temperature and humidity, and food and water ad libitum.
In vivo procedures (breeding) were performed in accord-
ance to the United Kingdom Animal (Scientific Proce-
dures) Act (1986) and approved by Imperial College
London’s Animal Welfare and Ethical Review Body.
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Organotypic brain cultures
Organotypic brain culture slices (OBCSs) were prepared
from postnatal day (P) 7 from wild-type, 5XFAD, Thy-1-
GFP, and double transgenics Thy-1-GFP/5XFAD mice.
The brains were sectioned in 300-μm coronal slices
using a vibratome (Leica VT1200 S); sections were then
mounted on semi-porous membrane filters (Millipore).
Brain slices were maintained in culture for 2 weeks in
nutrient media (Neurobasal-A medium (Invitrogen), 20%
normal horse serum, 20% HBSS, 0.5% glutamine, 0.5%
vitamin B27 supplement, and 1% antibiotics) and incu-
bated at 37 °C, 95%HR, 5%CO2. The nutrient medium
was replaced every 2 days for 2 weeks. Slices from
5XFAD mice were treated for 24 h with vehicle or with
1 mM L-AAA (Sigma) [18] in nutrient media. In another
set of experiments, WT OBSCs were treated with vehicle
or 0.6 μM synthetic Aβ42 [23] (Anaspect). After incuba-
tion, media was collected and brain slices were either
homogenized or fixed in 4% PFA for 24 h and kept at 4
°C in PBS and Na-azide.
Western blot
Brain slices were homogenized in RIPA buffer (1%
Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 150
mM NaCl, and 50 mM Tris-HCl, pH 7.2) supplemented
with cOmplete protease inhibitor (Roche) and phosphat-
ase inhibitor (Roche). A 50 μg of protein either from
homogenates or conditioned media were run on 4–12%
Tris-tricine gels (NuPAGE gels, Invitrogen). After trans-
ferring the gel to PVDF or nitrocellulose (for Aβ) mem-
branes, the membranes were blocked with 5% non-fat
semi skimmed milk diluted in Tris-buffered saline with
Tween (TBST) for 1 h. The primary antibody, diluted in
1% BSA and Na-azide, was subsequently incubated over-
night at 4 °C. The horseradish peroxidase secondary
antibody was incubated in 5% non-fat semi-skimmed
milk for 1 h at room temperature and bands were visual-
ized using ECL with a Gengnome XRQ device. Western
blots were analyzed using the ImageJ software and values
were normalized using β-actin as loading control.
Enzyme-linked immunosorbent assays (ELISA)
The levels of human Aβ40 and Aβ42 were determined
in homogenates using the High Sensitivity Human
Amyloid β42 and Aβ40 ELISA kits from Millipore. For
the analysis of mouse cytokines and chemokines in con-
ditioned media from the cultures, we used kits from
Peprotech (IL-1β, TNFα and IL-4) and Meso Scale Dis-
covery (Europe) (IL-6, IL-10, TGF-β1, MCP-1, and MIP-
1α). Concentrations were quantified according to the
manufacturer’s instructions and normalized to total pro-
tein concentration.
RNA extraction and quantitative PCR
mRNA extraction was conducted using the mirVana™
microRNA (miRNA) Isolation Kit according to manufac-
turer instructions (Thermofisher). Organotypic slices
were homogenized in Precellys tubes using a MiniLys
homogenizer (Bertin Technologies).
Polymerase chain reaction real-time cycling was
carried out with PowerUp™ SYBR™ Green Master Mix
(Thermofisher) and Quantitect Primer assays (Qiagen)
for mouse Neprilysin (Mme, Qiagen), IDE (5′-CAGAAG
GACCTCAAGAATGGGT-3′ and GCCTCGTGGT
CTCTCTTTATCT) and ApoE (Primers: ′-GGGACAGG
GGGAGTCCTATAA-3′ and 5′-ATTGGCCAGTCAGC
TCCTTC-3′) and normalized to GAPDH (5′-ACCACA
GTCCATGCCATCAC-3′ and 5′-TCCACCACCC
TGTTGCTGTA-3′). A 2-step method with an initial
reverse transcription and subsequent real-time cycling
on an Aria Mx qPCR workstation cycler was performed,
as reported previously [17].
Propidium iodide (PI) staining
PI was added at a concentration of 5 μg/ml, incubated
for 30 min in the conditioned media, and imaged with a
confocal microscope.
Immunofluorescence staining
Brain sections were permeabilized overnight in 0.25%
TBS-TX (TBS with triton X-100). Following this, sec-
tions were washed again in TBS and blocked for 60 min
in 10% goat serum/1%BSA in 0.1% TBS-TritonX and in-
cubated with the primary antibodies (anti-GFAP, 1:500,
anti-NeuN 1:500, anti-IBA1 1:500, anti-ALDH1L1 1:500,
anti-6C3 1:500) diluted in 2% goat serum, 0.2% BSA in
TBS-TX 0.02% for 48 h at 4 °C. Following this, sections
were washed 5 times for 10 min in TBS and incubated
with the secondary fluorescent antibodies (1:400 Alexa
Fluor; Invitrogen) in 2% goat serum, 0.2% BSA in TBS-
TX 0.02% overnight at 4 °C. After incubation with the
secondary antibodies, sections were washed 4 times with
TBS for 10 min. In the final wash, Hoechst solution (for
nuclear visualisation) was added (1:1000 in TBS) for 5
min. Following this, the slices were washed and mounted
using ProlongTM Gold antifade reagent (Invitrogen).
Sections were visualized with a confocal microscope
(Zeiss LSM-780). Immunohistochemistry staining was
quantified using the HALO software (Indico Labs) using
the area quantification FL module and represented as
percentage of the total image area.
Quantification of dendritic spines and analysis of
microglia
Dendritic spine size and density
Spine size was calculated as integrated brightness, using
an adapted version of custom written MATLAB code, as
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described previously [24, 25]. Briefly, the spine intensity
was measured by first drawing a region of interest
(ImageJ) across a length of dendrite taken from confocal
z-stacks. The region of interest covered the spine protru-
sions and a section of the adjacent dendrite. The region
of interest was then used to measure the fluorescence
intensity profile of the spines and adjacent dendrite. The
background was subtracted, and the intensity profile was
normalized to the adjacent dendrite to account for dif-
ferences in image intensity and background noise
between acquired z-stacks using MATLAB. A custom
written peak detection code (MATLAB) was then used
to identify fluorescence peaks in the normalized intensity
profile corresponding to individual spines. To identify
peaks, a threshold (50% greater than adjacent dendritic
fluorescence) was set based on visual inspection of the
smallest detectable spine peak. The number of spine
peaks was then divided by the length of the dendrite to
estimate the spine density and confirmed by manually
counting spines along 3-dimensional dendritic path-
lengths using ImageJ. For each spine, the area under
the normalized fluorescence spine peak (measured in
normalized dendrite units) was used as a proxy for
spine size.
Microglia analysis
For microglia analysis, a fluorescence intensity profile,
taken from a maximum intensity projection, was drawn
through the longest dimension of the cell body and
across a cross-section of the outer most tips of all associ-
ated processes. This intensity profile was then used to
estimate the soma size as well as the number, area, and
the perimeter of processes using custom written code in
MATLAB. Soma size was estimated by normalizing the
portion of the fluorescence trace corresponding to the
soma to the background and then calculating the area
under the curve for this section by multiplying the fluor-
escence peak by the width. The number of branch pro-
cesses was estimated by using custom written code
(MATALB) to detect peaks that were 25% greater than
background (threshold derived from visual inspection).
These peaks were then used to estimate the process area
by calculating the area under each fluorescence peak
and summing these values. Finally, the total process per-
imeter was calculated by adding the total number of
pixels covered by all detected peaks and dividing this
number by the scaling factor or the image (pixels/μm).
Statistical analysis
We calculated the number of animals and group sizes to
be used via InVivoStat, an R-based statistical package
[26]. The data was analyzed using Graphpad Prism 8
software (Graphpad Software Inc), using unpaired
Student’s t tests, repeated-measures 1- or 2-way analyses
of variance, and followed by Tukey post hoc analysis.
The Kolmogorov-Smirnov test was applied to confirm
normal distribution. All quantitative data are given as
mean ± SEM. Probability of less than 0.05 was con-
sidered significant.
Results
L-AAA treatment results in astrocytic death in
organotypic brain cultures
To determine the effectiveness of the L-AAA treatment
on selective astrocytic toxicity and death [18, 27], sec-
tions were incubated at two different time points and
stained with GFAP and Aldehyde dehydrogenase 1A
(Aldh1a1) for astrocytes and NeuN antibodies for neu-
rons. Our results show a remarkable reduction on GFAP
and Aldh1a1 staining after 24 h treatment (Fig. 1a–d,
Fig. S1A-F), without affecting the viability and number
of neurones (Fig. 1e–h and j). However, at 48 h, tissue
organization was largely disrupted (Fig. S1G). To prove
that at 24 h the sections were not damaged, slices were
stained with propidium iodide (PI), demonstrating that
the incubation with L-AAA for 24 h did not affect tissue
integrity (Fig. S1H-K). Therefore, 24 h was selected as
the optimal L-AAA length of exposure and was used in
the following experiments.
Pharmacological ablation of astrocytes leads to an
increase in the expression of pro-inflammatory markers
We next examined whether the loss of astrocytes
affected the density of other glial cells, such as microglia.
The staining of microglia with Iba-1 antibody in cortex
and hippocampus (Fig. 2a–d) showed an increase in the
density of microglia in sections from 5XFAD mice com-
pared with WTs, which was significant in the hippocam-
pus (Fig. 2d). However, it did not reveal changes in the
density of microglia in sections of 5XFAD mice treated
with 1 mM L-AAA compared with vehicle treated con-
trols (Fig. 2a–d). However, high magnification images
showed a change in the morphology of microglia, being
more amoeboid-like and less ramified in transgenic
OBCSs and in all sections following treatment with L-
AAA, indicative of an activated phenotype (Fig. 2).
Analysis of the morphological parameters of microglia
demonstrated a reduction in the number of processes, in
the process area and the process perimeter of slices
treated with L-AAA (Fig. 2e, Fig. 2f), while the soma size
was increased, particularly in microglia of the transgenic
hippocampus, typical of a reactive state (Fig. 2f)
Following this, we measured the levels of various pro-
and anti-inflammatory cytokines and chemokines in the
conditioned media of the organotypic cultures (Fig. 3).
Interestingly, media from transgenic 5XFAD slices
showed different cytokine profile, with higher Il-1β levels
and reduced TNFα, TGFβ, and MCP1 expression,
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compared with WT sections, in line with the changes
found on microglia morphology (Fig. 3a, d, f, and g). In
addition, we found that the expression of pro-
inflammatory cytokine IL-6 was increased in both WT
and transgenic sections treated with L-AAA (Fig. 3b),
while other cytokines and chemokines mostly produced
by astrocytes, such as TGF-β1, MCP1(CCL2), and MIP-
1α (CCL3) [28], were reduced by incubation with L-
AAA only in wild-type sections (Fig. 3f–h). IL-1β, IL-10,
and IL-4 levels were unchanged by L-AAA treatment in
all groups analyzed (Fig. 3c–e).
These results suggest that depletion of astrocytes re-
sults in an increase of the pro-inflammatory profile in
organotypic brain cultures.
L-AAA treatment affects Aβ degradation mechanisms
To investigate the effects of pharmacological loss of as-
trocytes on amyloid-β levels, transgenic sections treated
with L-AAA overnight were homogenized and the
expression of Aβ subtypes was measured by ELISA. At
this age, cultures do not show Aβ deposition in plaques
(Fig. S1M). Our results show that L-AAA treatment led
to a 65% increase in the levels of Aβ1-42, while the
expression of Aβ1-40 was only slightly increased com-
pared with vehicle controls (Fig. 4a).
To determine the potential mechanisms leading to the
increase on Aβ expression, we measured the levels of a
full-length APP and the CTFs in OBCS homogenates.
The expression of full-length APP and the CTFs were
found unaltered after L-AAA treatment (Fig. 4b), sug-
gesting that the cleavage of APP was not affected by the
loss of astrocytes. In agreement with these results, the
expression of the β-secretase (BACE1) did not change
either in any of the groups analysed (Fig. 4b).
We next analyzed whether the mechanisms of clear-
ance and degradation of Aβ were affected by L-AAA,
since we have previously observed that they were altered
in a model of genetic ablation of astrocytes [17]. In
agreement with our previous report, we found that L-
AAA induced a significant reduction of the protein and
mRNA levels of neprilysin (Fig. 4c, d) and insulin-
degrading enzyme (Ide) gene expression (Fig. 4c, e).
ApoE protein levels were only reduced in WT sections
(Fig. 4f, g).
To confirm that the loss of astrocytes affects the
mechanisms of Aβ clearance and degradation, we treated
Fig. 1 L-AAA reduces the density of astrocytes but does not affect the number of neurons. Representative images and quantification of
astrocytes and neurons in OBCSs treated with 1mM L-AAA or vehicle for 24 h. a–d GFAP expression in the hippocampus of OBCSs from WT and
5XFAD mice treated with 1mM L-AAA or vehicle for 24 h. e–h Expression of NeuN in the hippocampus of OBCSs from WT and 5XFAD mice. i
Quantification of % area stained with GFAP (n=15–16). j Quantification of % area stained with NeuN (n=4–5). Values shown in graphs represent
the mean value ± SEM. Statistical analysis included a Student’s t test, **P<0.01 ***P<0.001. Scale bar = 100 μM
Davis et al. Journal of Neuroinflammation           (2021) 18:73 Page 5 of 12
Fig. 2 L-AAA treatment affects the morphology of microglia in the cortex and hippocampus. a Representative images and b quantification of the
% area of Iba-1 staining in cortex of WT and 5XFAD OBCSs treated with L-AAA for 24h (n=7–9). c Representative images and d quantification of
the % area of Iba-1 staining in hippocampus of WT and 5XFAD OBCSs treated with L-AAA for 24 h. Scale bar=100 μM (n=8-11). e Analysis of
process number, process area, process perimeter, and soma size of Iba-1-positive microglia in the cortex (e) and hippocampus (f) (n=7–11). Values
shown in graphs represent the mean value ± SEM. Statistical analysis included a one-way ANOVA, *P<0.05; **P<0.01; ***P<0.001
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wild-type slices with 0.6-μM synthetic Aβ1-42, in the
presence or absence of 1 mM L-AAA for 24 h, to allow
the measurement of the stability of Aβ. Analysis of Aβ
in culture media by Western blot revealed higher levels
of Aβ in L-AAA treated sections (>56%) compared with
vehicle-treated control (Fig. 4h, i). In addition, the ex-
pression levels of IDE were significantly reduced in the
media of cultures treated with L-AAA (Fig. 4h, i). These
data indicate that the stability of synthetic Aβ1-42 pep-
tide in the medium was increased by incubation with L-
AAA, due to reduced Aβ degradation.
Pharmacological ablation of astrocytes leads to dendritic
spine loss
To examine the effects of pharmacological ablation of
astrocytes on synaptic connectivity, we measured the
number and size of dendritic spines in organotypic cul-
tures from brains of thy-1-GFP transgenic mice incu-
bated with 0.6-μM synthetic Aβ1-42 or crossed with
5XFAD mice. Quantification of dendritic spines revealed
a 33% reduction in their density in the CA1 area of the
hippocampus in all groups following L-AAA treatment
(Fig. 5a, b).
Interestingly, spine size was reduced in 5XFAD mice
and in wild-type sections treated with Aβ1-42 compared
with wild-type controls. Pharmacological ablation of as-
trocytes resulted in a further 47% decrease in the spine
size only in slices from 5XFAD mice and not in wild-
type slices incubated with synthetic Aβ (Fig. 5). These
results are in agreement with the reductions on synaptic
density observed in our previous publication, using
models of genetic ablation of astrocytes [17].
Discussion
In the past few years, several studies have analyzed the
role of astrocytes in vivo using animal models of AD.
The results of the effects of ablation of astrocytes on
amyloid pathology have been sometimes contradictory,
depending on the approach and the animal model used.
The first reports from 2013 from Kraft et al. [29] sug-
gested that the genetic depletion of GFAP and vimentin
in APP/PS1 mice resulted in increased amyloid plaque
deposition, while in a different study GFAP and vimen-
tin deficiency did not lead to differences in amyloid load
[30]. In contrast, reduction of astrocytic activation by
viral injection of the Gfa2–VIVIT construct [31] de-
creased Aβ pathology in APP/PS1 transgenic mice. More
recently, we have reported that the ablation of reactive
astrocytes in double transgenic APP23/GFAP-TK mice
significantly augmented the levels of monomeric Aβ in
brain homogenates, without affecting the plaque load or
the number of plaques [17]. Therefore, it seems that the
consensus is that the reduction in astrocyte density leads
to higher amyloid levels, without changes in its aggrega-
tion or deposition. These results are in line with the data
obtained in the present study, showing that pharmaco-
logical ablation of astrocytes leads to higher Aβ levels.
Regarding the molecular mechanism involved in the
changes in amyloid pathology, the results from our stud-
ies suggest that astrocytes are involved in mechanisms of
Fig. 3 L-AAA treatment affects the neuroinflammatory profile in the cortex. Quantification of expression of a TNFα, b IL-6, c IL-4, d IL-1β, e IL-10, f
TGF-β, g MCP1, and h MIP-1α by ELISA in conditioned media from OBCSs of WT and 5XFAD mice treated with L-AAA for 24 h (n=6–18). Values
shown in graphs represent the mean value ± SEM. Statistical analysis included one-way ANOVA with Tukey’s multiple-comparison post-hoc test.
*P<0.05; **P<0.01; ***P<0.001
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Fig. 4 (See legend on next page.)
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amyloid degradation and clearance, rather than affecting
amyloid generation. We have demonstrated, using two
different approaches, that the expression of neprilysin
was decreased following astrocytic loss ([17] and present
study). The effect on Apo-E protein expression was only
significant in wild-type sections by L-AAA treatment. In
addition, we observed that Ide gene expression and IDE
secreted in the media was reduced in OBCSs treated
with L-AAA, potentially contributing to the stability of
amyloid in the culture media. Neprilysin is mainly
expressed in neurons [32] but can also be found in acti-
vated astrocytes and microglia [15], while IDE is pro-
duced and secreted by neurons, oligodendrocytes, and
microglia in the brain [33], and ApoE is mainly pro-
duced in astrocytes but can be synthesized by microglia
[15]. It is possible that indirectly, loss of astrocytes could
affect the levels of neprilysin and IDE in other cell types.
In addition, astrocytes are involved in the clearance of
Aβ through the BBB via the AQP4 channels expressed
in their end feet and are also able to phagocytose amyl-
oid [6, 34, 35]. Interestingly, recent studies of single cell
transcriptomics have shown that the APOE gene was
repressed in Alzheimer’s disease oligodendrocyte precur-
sor cells (OPC), oligodendrocyte, and astrocyte subclus-
ters, while it was increased in the microglial AD
subcluster [36, 37]. Therefore, all of these observations
point out to a protective role of astrocytes in AD, par-
ticularly mediating amyloid degradation and clearance,
which can be compromised in AD brain at later stages.
In this study, we also investigated the relationships be-
tween microglia and astrocytes in WT and transgenic
OBCSs. We observed that microglia from transgenic cul-
tures seemed to have a different phenotype, compared to
WT sections, showing more amoeboid-like morphology
and higher Il-1β levels and a reduction in TGF-β and
MCP1, representative of a pro-inflammatory profile. In-
triguingly, TNFα expression was reduced in media from
5XFAD sections compared with WT OBCSs; however,
the role of this cytokine in AD is contentious, because it
can protect neurons against amyloid toxicity or induce
apoptosis [38]. We also show that L-AAA treatment did
not influence the density of microglia, but led to a react-
ive phenotype, contributing to a pro-inflammatory envir-
onment. Our data indicate that the effect of L-AAA on
cytokine and chemokine expression is different in WT
and transgenic sections, suggesting that the phenotype
of the astrocytes could be different in transgenic ani-
mals. Interestingly, L-AAA induced a reduction in cyto-
kines and chemokines produced in astrocytes (such as
TGF-β, MIP-1α, and MCP1 as well as ApoE) in
(See figure on previous page.)
Fig. 4 Loss of astrocytes affects Aβ clearance mechanisms. a Quantification of Aβ subtypes by ELISA in 5XFAD OBCSs homogenates (n=4–5). b
Quantification and representative Western blot of APP, CTFs, and BACE1 expression in 5XFAD OBCS homogenates (n=6–10). c Representative
Western blot of Neprilysin and IDE protein expression in WT and 5XFAD treated with vehicle or L-AAA. d Quantification of Neprilysin protein and
gene expression in WT and 5XFAD treated with vehicle or L-AAA (n=6–12). e Quantification of IDE protein and gene expression in WT and
5XFAD OBCSs treated with vehicle or L-AAA (n=6–12). f Representative Western blots and g quantification of ApoE protein and gene expression
in WT and 5XFAD OBCSs OBCSs treated with vehicle or L-AAA (n=5–10). h Representative Western blot of synthetic human Aβ1-42 and IDE in
conditioned media from WT OBCSs treated for 24h with L-AAA or vehicle i quantification of Aβ42 by Western blot (n=12–18) and quantification
of IDE protein expression in conditioned media from WT OBCSs treated for 24 h with synthetic human Aβ1-42 with vehicle or L-AAA (n=12–18).
Values shown in graphs represent the mean value ± SEM. Statistical analysis included a Student’s t test, *P<0.05; **P<0.01; ***P<0.001
Fig. 5 Ablation of astrocytes alters synaptic density in OBCSs. (a) Quantification and (b) representative images of dendritic spine density and size
in hippocampus (CA1 and CA3 areas) of organotypic cultures of thy-1-GFP transgenic mice crossed with 5XFAD mice or WTs incubated with 0.6-
μM synthetic Aβ and treated for 24 h with L-AAA or vehicle (n=12–18). Scale bar= 1 µm values shown in graphs represent the mean value ± SEM.
Statistical analysis included one-way or two-way ANOVA with Tukey’s or Holm-Sidaks multiple-comparison post-hoc test, *P<0.05;
**P<0.01; ***P<0.001
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organotypic cultures of wild-type mice, with no changes
in transgenic slides. However, pro-inflammatory cyto-
kine IL-6 produced by microglia and astrocytes was in-
creased in both WT and transgenic slices, indicating the
elevation on inflammatory cytokines following incuba-
tion with L-AAA may not be exclusively secondary to an
increase in Aβ. Therefore, our results indicate that astro-
cytes are different in WT and transgenic mice and may
contribute to the activation of other glial cells, affecting
their morphology and inflammatory profile. This is in
line with studies showing that astrocytes can trigger
microglia activation and regulate their cellular functions
through the release of cytokines, chemokines, and
growth factors [39].
Similarly, in this report, we demonstrate the effect of
pharmacological ablation of astrocytes on synaptic dens-
ity, which contributes to the exacerbation of the spine
density and size in transgenic 5XFAD sections. Treat-
ment with synthetic Aβ42 in WT slices had no effect in
spine density. Previous reports have looked at the effect
of injections of fibrillar Aβ42 in rat brain and detected a
reduction in synaptic spines [40]; however, the effect of
synthetic Aβ might depend on the concentration of
amyloid, the incubation time, and the presence of fibril-
lar or oligomeric amyloid [41]. In wild-type tissue, L-
AAA treatment also seems to affect the number of
dendritic spines in sections treated with synthetic Aβ,
but not their size. In previous studies, it was shown that
L-AAA affected the cellular and synaptic properties in
the lamprey spinal cord, suggesting a role of astrocytes
in network locomotor activity [42]. These results
reinforce the function of astrocytes regulating synapsis
in AD, shown by us and others [17, 43]. These effects
could be a consequence of their implications on Aβ
clearance, the production of anti-inflammatory media-
tors, and/or the potential release of neurotrophic factors
and metabolites [3].
Conclusions
In conclusion, the present report shows the effects of
the elimination of all types of astrocytes in an ex vivo
model of AD (in contrast with previous studies, targeting
only GFAP positive astrocytes) and allows the compari-
son with wild-type animals. In fact, we show that the
profile of astrocytes in WT animals seems to be different
to that in transgenic mice. Our results support the role
of astrocytes on the removal of Aβ and the regulation of
neuroinflammation in AD. In addition, the effects of
L-AAA on dendritic spine density and size suggest a neu-
roprotective role of astroglia on memory processes.
Although the use of organotypic cultures of brain sec-
tions and of a chemical (L-AAA) to remove astrocytes
has its limitations, this approach has allowed us to use a
straightforward technology to elucidate the functions of
astrocytes on amyloid pathology, neuroinflammation,
and synaptic density. In addition, it is a useful tool for
future studies on AD and other neurodegenerative
diseases, avoiding the use of large numbers of animals
and reducing animal suffering. In the future, it would be
interesting to determine whether there is an effect of
L-AAA using slices from the adult brain, which
would have the advantage of mature adult brain
morphology, metabolism, and presence of tau or Aβ
deposition surrounded by activated glia.
New therapeutic approaches for AD could be based on
the neuroprotective role of astrocytes, using pharmaco-
logical tools enhancing astrocytic proliferation. These ef-
fects could be promising even at late stages of the
disease, when the formation of new synapsis and neuro-
inflammation could be more important than their func-
tion in regulating amyloid levels.
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